CRISPR Therapeutics

CRISPR Therapeutics AG
FormerlyInception Genomics
TypePublic
Nasdaq: CRSP
ISINCH0334081137
IndustryBiotechnology
Founded2013 (2013)
Founders
HeadquartersZug, Switzerland
Key peopleSamarth Kulkarni (CEO)
RevenueDecrease US$37.3 million (2024)
Decrease US$−467 million (2024)
Decrease US$−366 million (2024)
Total assetsIncrease US$2.24 billion (2024)
Total equityIncrease US$1.93 billion (2024)
Number of employees
393 (2024)
Websitecrisprtx.com
Footnotes

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.